Home News About Us Products Contact Us

About Us
Frank McKeon Frank McKeon

Dr. Frank McKeon, Professor of Cell Biology at Harvard University, is an internationally recognized authority and pioneer in the fields of cell biology, signal transduction, and p53-related genes. He has discovered fundamental mechanisms underlying T cell activation, chromosome segregation, and stem cell regeneration. The p63 gene was discovered in his laboratory as was the function of this gene in stem cells of the prostate, breast, and epidermis. In addition, he has demonstrated the value of p63 in the diagnosis of cancers of the prostate and breast and produced the monoclonal antibodies to p63 that are in world-wide use for cancer detection and stem cell analysis. Dr. McKeon obtained his B.S. in Biology at Pomona College (1979) and his Ph.D. in biochemistry and biophysics from the University of California, San Francisco (1984). [ Read more ]

Peter McKeon
Peter McKeon

Peter McKeon is President of the company today. Mr. McKeon joined the Company in 2005 and drives the Company's strategic direction and business growth. He has extensive experience in scaling startup companies to profitability. Prior to joining AsymmetRx, McKeon founded and sold various companies in the sales and distribution segments. He earned a B.S. in Marketing from the University of Rhode Island.

Matt Vincent
Matt Vincent

Matthew Vincent, Ph.D. is the Director of Business Development at Advanced Cell Technology, Inc. Prior to joining Advanced Cell Technology, he was a partner at Ropes & Gray LLP and worked in the field of health and life science law since 1991 practicing principally in the areas of intellectual property and business and trade regulation as a patent agent and attorney. Matt earned a B.S. in Chemistry, summa cum laude, in 1986 and a Ph.D. in Biochemistry in 1991 from Tufts University School of Medicine. He received his J.D., cum laude, from Suffolk University Law School in 1996. Matt has extensive experience in all areas of biotechnology businesses, and is also a co-founder of Calando Pharmaceuticals and Multiclonal Therapeutics.

Annie Yang

Annie Yang, Ph.D. in biological sciences with over 10 years research experience, including gene discovery, functional analysis, cell-based screening assays, target validation, and drug efficacy studies. Extensive publication record and co-inventor on two U.S. patents. Experience with multi-disciplinary collaborations in the biotechnology/pharmaceutical industry and academia. Her specialties lie in cancer biology and signaling pathways; in vitro and in vivo preclinical models for target validation and evaluation of therapeutic antibodies and protein biologics.

Outside Counsel

Steven Bauer, Esq., Daryn Grossman, Esq., Amy Crafts, Esq. Proskauer Rose LLP, Boston, MA